GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIK · Mar 31, 2023

Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001171843-23-003106General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.66% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-9.54% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

108.95% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

60.23% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-33.10% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

22.15% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

9.80% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
4.79%
Current
3.66%
Delta
-1.13%
Cash Generation Decreased
Previous
2.82%
Current
-9.54%
Delta
-12.36%
Inventory Pressure Increased
Previous
25.45%
Current
108.95%
Delta
83.50%
Margin Increased
Previous
59.89%
Current
60.23%
Delta
0.34%
Profitability Decreased
Previous
-12.42%
Current
-33.10%
Delta
-20.68%
R And D Intensity Increased
Previous
18.04%
Current
22.15%
Delta
4.11%
Sbc Intensity Increased
Previous
9.16%
Current
9.80%
Delta
0.64%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_DECREASED →Transitioned To · ANIK CASH_GENERATION_DECREASED →Transitioned To · ANIK INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIK MARGIN_INCREASED →Transitioned To · ANIK PROFITABILITY_DECREASED →Transitioned To · ANIK R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIK SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.